Silence Therapeutics plc (SLN) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$89M, a net margin of -15851.9%; the best year in this period was 2018 with -$24M.
Over the twelve months to June 30, 2026, revenue was $615000 and net income -$60M.
Free cash flow was -$62M in fiscal 2025 and positive in 2 of the 8 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $615000 | $559000 | $43M | $32M | $22M | $17M | $7M | $322180 | — |
| Gross profit | — | $344000 | $31M | $19M | $8M | $7M | $2M | $322180 | — |
| Operating income | — | -$91M | -$63M | -$64M | -$61M | -$62M | -$49M | -$30M | -$26M |
| Net income | -$60M | -$89M | -$45M | -$54M | -$50M | -$53M | -$44M | -$26M | -$24M |
| EPS (diluted) | $-1.27 | $-1.43 | $-0.73 | $-0.87 | $-0.81 | $-0.85 | $-0.71 | $-0.42 | $-0.38 |
| R&D | — | $68M | $68M | $57M | $44M | — | — | — | — |
| Revenue growth | — | −98.7% | +36.7% | +46.1% | +29.4% | +131.3% | +2145.3% | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$42M | -$62M | -$68M | -$49M | -$57M | $9M | -$15M | $2M | -$21M |
| Capital spending | -$907606 | -$55000 | -$211000 | -$56000 | -$173000 | -$2M | -$697468 | -$11884 | -$166400 |
| Free cash flow | -$42M | -$62M | -$68M | -$50M | -$57M | $7M | -$15M | $2M | -$22M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — |
| Stock-based pay | — | $8M | $16M | $16M | $13M | $12M | $6M | $771120 | $871680 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $85M | $147M | $69M | — | — | — | — | — |
| Debt | — | $160000 | $117000 | $346000 | — | — | — | — | — |
| Equity | — | $62M | $134M | $22M | $27M | $12M | $12M | $28M | $45M |
| Total assets | — | $131M | $203M | $119M | — | — | — | — | — |
| Shares (diluted) | 47M | 62M | 62M | 62M | 62M | 62M | 62M | 62M | 62M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 61.5% | 72.7% | 59.3% | 37.8% | 39.9% | 32.4% | 100.0% | — |
| Operating margin | — | -16292.8% | -146.4% | -203.5% | -281.9% | -369.0% | -676.4% | -9317.2% | — |
| Net margin | -9748.5% | -15851.9% | -104.7% | -171.4% | -232.4% | -317.4% | -614.1% | -8025.4% | — |
| FCF margin | -6872.5% | -11149.6% | -156.8% | -156.5% | -264.2% | 44.3% | -213.0% | 704.1% | — |
| ROIC | — | -115.2% | -37.3% | -227.7% | -177.2% | -428.9% | -357.3% | -93.1% | -52.6% |
| ROE | — | -142.2% | -33.8% | -246.6% | -184.9% | -429.3% | -359.3% | -93.7% | -52.5% |
Frequently asked questions
What is Silence Therapeutics’s annual revenue?
$559000 in fiscal 2025 and $615000 over the twelve months to June 30, 2026.
How much profit does Silence Therapeutics make?
Net income was -$89M in fiscal 2025 (net margin -15851.9%).
Is Silence Therapeutics’s revenue growing?
No: revenue fell 98.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.